Alambeladi S, Hosseiny S, Jafarinia M, Dianatpour M. 2021. Use of dual-transfection for programmed cell death protein 1 disruption mediated by CRISPR-Cas9 in human peripheral blood mononuclear cells. Iran J Basic Med Sci 24(1):44-50.

Bally AP, Austin JW, Boss JM. 2016. Genetic and epigenetic regulation of PD-1 expression. J Immunol 196(6):2431-2437.

Blank C, Kuball J, Voelkl S, Wiendl H, Becker, B, Walter B, ... and Mackensen A. 2006. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 119(2):317-327.

Cho SW, Kim S, Kim JM, Kim JS. 2013. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31(3):230-232.

Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, ... & Zhang F. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121):819-823.

Cong L, Zhang F. Genome engineering using CRISPR-Cas9 system. 2015. Methods Mol Biol 1239:197‐217.

Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, ... & Zhang, F.2013.  DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31(9):827-832.

John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, ... & Darcy PK. 2013. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 19(20):5636-5646.

Kallimasioti-Pazi EM, Thelakkad Chathoth K, Taylor GC, Meynert A, Ballinger T, Kelder MJ, ... & Wood AJ. 2018. Heterochromatin delays CRISPR-Cas9 mutagenesis but does not influence the outcome of mutagenic DNA repair. PLoS Biol 16(12): 2005595.

Keir ME, Butte MJ, Freeman GJ, Sharpe AH. 2008. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704.

Lioyd A, Vickery ON, Laugel B. 2013. Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies, Front Immunol 5(4):221.

Luke JJ, Ott PA. 2015. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget 6(6):3479-3492.

Makarova KS, Haft DH, Barrangou R, Brouns S J, Charpentier E, Horvath P, ... & Koonin E V. 2011. Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 9(6):467-477.

Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, ... & Church GM. 2013. RNA-guided human genome engineering via Cas9. Science 339(6121):823-826.

Pen JJ, Keersmaecker BD, Heirman C, Corthals J, Liechtenstein T, Escors D, ... & Breckpot, K. 2014. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther 21(3):262-271.

Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA. 2013. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152(5):1173-1183.

Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, ... & Zhang F. 2013. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154(6):1380-1389.

Su S, Hu B, Shao J, Shen B, Du J, Du Y, ... & Liu B. 2016. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep 286:20070.

Tumeh PC, Harview CL, Yearley JH, Shintaku I P, Taylor EJ, Robert L, ... & Ribas A. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568‐571.

Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. 2009. PD-1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25 (Hi) regulatory T cells. Int Immunol 21(9):1065-1077.